arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Rezolute, Inc.

RZLT
$4.67 ▼ -0.03 (-0.53%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Rezolute, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $354.9M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -38.9%
FCF / Share $-0.91
Trailing P/E
Price / Book 2.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-74.41M
↓ -8.7%
FCF / Share Free cash flow per share
$-0.91
↑ +18.5%
Long-Term Debt Long-term obligations
$13.97M
↑ +127.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
18
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 65 quarters